StockData
Coherus Oncology, Inc. logo

Coherus Oncology, Inc. (CHRS) stock

CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3057% below fair value
$0.48−0.03 (-5.42%)

Close on Nov 17, 2026Market cap $73.93MP/E –Yield –

Earnings

Coherus Oncology's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 8, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$14.30M
+23.3% on a year earlier
Non-GAAP net loss from continuing operations per share on a diluted basis, Q3 FY2026
-$0.20
-$0.33 a year earlier
Latest guidance
Issued
Jan 13, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Coherus Oncology's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Mar 8, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 9, 2026after the close$14.30M+23.3%-$0.25-$0.20Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026during market hours$14.30M+38.8%-$0.22-$0.19Release
Q1 FY2026ended Mar 31, 2026May 11, 2026during market hours$12.30M+61.8%––Release
Q4 FY2025ended Dec 31, 2025Mar 9, 2026during market hours$12.70M–-$0.39-$0.34Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025during market hours$11.60M-83.6%-$0.38-$0.33Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025during market hours$10.30M-84.2%-$0.39-$0.34Release
Q1 FY2025ended Mar 31, 2025May 12, 2025during market hours$7.60M-90.1%–-$0.35Release
Q4 FY2024ended Dec 31, 2024Mar 10, 2025during market hours––-$0.44-$0.28Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024during market hours$70.80M-5.1%-$0.09-$0.01Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024during market hours$65.00M+10.7%-$0.11-$0.14Release
Q1 FY2024ended Mar 31, 2024May 9, 2024during market hours$77.10M+138.0%$0.83-$0.32Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Coherus Oncology's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
RevenuesFY2028$150.00M – $200.00M–NewJan 13, 2026

Guidance history

Every forecast Coherus Oncology put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Jan 13, 2026RevenuesFY2028$150.00M – $200.00MNew
Jan 13, 2025Q4 expected net revenuesQ4 FY2024$49.00M – $54.00MNew
Nov 6, 2024combined R&D and SG&A expensesFY2024$250.00M – $260.00MLowered
Aug 8, 2024combined R&D and SG&A expensesFY2024$250.00M – $265.00MReaffirmed
May 9, 2024combined R&D and SG&A expensesFY2024$250.00M – $265.00MReaffirmed
Mar 13, 2024combined R&D and SG&A expensesFY2024$250.00M – $265.00MNew
Nov 6, 2023combined R&D and SG&A expensesFY2023$300.00M – $310.00MLowered
Nov 6, 2023stock-based compensation expenseFY2023$40.00M – $45.00MLowered
Nov 6, 2023net product revenueFY2023$250.00M – $260.00MLowered
Aug 2, 2023combined R&D and SG&A expensesFY2023$315.00M – $335.00MReaffirmed
Aug 2, 2023net product revenueFY2023$275.00MReaffirmed
May 8, 2023combined R&D and SG&A expensesFY2023$315.00M – $335.00MReaffirmed
May 8, 2023net product revenueFY2023$275.00MNew
Mar 6, 2023combined 2023 R&D and SG&A expensesFY2023$315.00M – $335.00MNew
Nov 8, 2022combined 2022 R&D and SG&A expensesFY2022$375.00M – $385.00MLowered
Aug 4, 2022combined 2022 R&D and SG&A expensesFY2022$375.00M – $395.00MLowered
May 5, 2022combined R&D and SG&A expensesFY2022$395.00M – $430.00MLowered
Feb 17, 2022combined R&D and SG&A expensesFY2022$415.00M – $450.00MNew
Nov 8, 2021R&D and SG&A expensesFY2021$370.00M – $400.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Coherus Oncology filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Update
  4. Update
  5. Update
  6. Results
  7. Results
  8. Results
  9. Results
  10. News
  11. Results
  12. Results
  13. Update
  14. Results
  15. Update

See a number that looks wrong?